2025-05-26-Jefferies-龙沙集团（LONN）_首日初览_一个龙沙_7页_178kb

Lonza Group AG Equity Research Summary

Date: May 27, 2025

Key Points

1. Rating & Price Target

   • Rating: BUY
   • Price Target (PT): CHF715.00 (up 26% from current price of CHF568.00).
   • Historical PT Trends: The price target has shown upward revisions in recent months, reflecting confidence in the company’s growth potential.

2. New Operating Model "One Lonza"

   • Implemented as of April 1, 2025, with financials for FY24 and 1H24 released ahead of 1H25 results.
   • The model restructures operations into three CDMO segments and a to-be-divested capsules business.
   • Segments:
     • Integrated Biologics: Combines mammalian and drug product services with licensing.
     • Advanced Synthesis: Focuses on small molecules and bioconjugates.
     • Specialized Modalities: Includes cell & gene therapies (CGT), mRNA, microbial technologies, and bioscience products.

3. Financial Highlights

   • Bioconjugates:
     • Maintains margins aligned with small molecules.
     • Constitutes ~10% of biologics revenues.
     • Capital expenditure of CHF151m (18% of biologics Capex), signaling growth investment.
   • mRNA & Microbial:
     • Combined margin of 20%, which is accretive to CGT division margins but dilutive to biologics margins.
     • Allocated 8% of biologics Capex spend, lower than their 11% revenue share.
   • Capex Allocation:
     • Bioconjugates receives significant Capex support, highlighting strategic focus.
     • mRNA and microbial sectors have lower Capex intensity.

4. Valuation Approach

   • Uses sum-of-the-parts DCF, group DCF, segment comparables, historical multiples, and growth scenarios.
   • Analyzes metrics such as EBITDA, EPS, free cash flow (FCF), EV/EBITDA, P/E, and P/CF for forecasting.

5. Risk Factors

   • Failing to secure future drug manufacturing contracts.
   • Regulatory site inspection deficiencies.
   • Weak demand or margin pressures.
   • Inability to achieve efficiency/productivity gains.

6. Analyst Certifications

   • Both James Vane-Tempest and Christopher Richardson certify the report reflects their personal views and that compensation is not tied to recommendations.
   • Non-US analysts (e.g., James Vane-Tempest, Christopher Richardson) are not registered with FINRA and may not be subject to its rules.

7. Investment Recommendations & Disclosures

   • Buy-rated stocks are highlighted as having high potential for total returns (15%+).
   • Disclosures include potential conflicts of interest due to Jefferies’ business relationships with covered companies.
   • Legal restrictions apply to distribution in various regions (e.g., Canada, Singapore, Hong Kong), and the report is intended solely for professional/institutional investors.
   • No guarantee of returns, and past performance does not predict future results.

8. Market Capitalization & Liquidity

   • Current market cap: CHF41.0B ($49.9B).
   • Float: 97.1% (ADV MM: USD118.15).
   • Price targets are converted using the prior trading day’s exchange rate (unless specified).

9. Recommendation History

   • Lonza has consistently been rated BUY over the past three years, with multiple PT updates (e.g., CHF700.00 in May 2022, CHF729.00 in January 2025).

Summary of Implications

The report emphasizes Lonza’s strategic shift under the "One Lonza" model, prioritizing high-growth CDMO segments like bioconjugates, CGT, mRNA, and microbial technologies. Key drivers include targeted Capex allocation to bioconjugates and the potential accretion to CGT margins, which could improve long-term profitability. Risks remain centered on contract acquisition, regulatory compliance, and market demand volatility. Analysts maintain a BUY rating, citing growth opportunities and strong financial metrics, though investors are cautioned about potential conflicts of interest and non-guaranteed returns.

Note: The summary excludes legal disclaimers, specific disclosure links, and non-financial details (e.g., analyst contact information) as per the user’s instructions.